HitGen 대차 대조표 상태

재무 상태 기준 확인 5/6

HitGen 의 총 주주 지분은 CN¥1.4B 이고 총 부채는 CN¥207.0M, 이는 부채 대 자기자본 비율을 14.8% 로 가져옵니다. 총자산과 총부채는 각각 CN¥1.7B 및 CN¥320.8M 입니다. HitGen 의 EBIT는 CN¥43.5M 이며 이자보상배율은 -2.6 입니다. CN¥942.6M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

14.8%

부채 비율

CN¥206.98m

부채

이자 보상 비율	-2.6x
현금	CN¥942.61m
주식	CN¥1.40b
총 부채	CN¥320.76m
총 자산	CN¥1.72b

최근 재무 상태 업데이트

HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly

Jun 06

Recent updates

Optimistic Investors Push HitGen Inc. (SHSE:688222) Shares Up 51% But Growth Is Lacking

Oct 08

HitGen Inc. (SHSE:688222) Shares Could Be 26% Above Their Intrinsic Value Estimate

Jul 03

HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly

Jun 06

HitGen Inc.'s (SHSE:688222) 28% Jump Shows Its Popularity With Investors

Mar 07

재무 상태 분석

단기부채: 688222 의 단기 자산 ( CN¥1.1B )이 단기 부채( CN¥69.3M ).

장기 부채: 688222 의 단기 자산( CN¥1.1B )이 장기 부채( CN¥251.5M ).

부채 대 자본 내역 및 분석

부채 수준: 688222 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: 688222 의 부채 대 자기자본 비율은 지난 5년간 0.4% 에서 14.8% 로 증가했습니다.

부채 범위: 688222 의 부채는 영업 현금 흐름 ( 76.5% )에 의해 잘 충당되었습니다.

이자 보장: 688222 지불하는 것보다 더 많은 이자를 벌기 때문에 이자 지불 보장은 문제가 되지 않습니다.

HitGen 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly

Recent updates

New minor risk - Share price stability

Price target increased by 43% to CN¥16.90

Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.031 in 3Q 2023)

Now 23% overvalued after recent price rise

Optimistic Investors Push HitGen Inc. (SHSE:688222) Shares Up 51% But Growth Is Lacking

New minor risk - Share price stability

HitGen Inc. to Report Q3, 2024 Results on Oct 26, 2024

Now 20% overvalued

Now 25% overvalued

HitGen Inc. (SHSE:688222) Shares Could Be 26% Above Their Intrinsic Value Estimate

HitGen Inc. to Report First Half, 2024 Results on Aug 29, 2024

HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly

HitGen Inc., Annual General Meeting, May 22, 2024

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.02 loss in 1Q 2023)

HitGen Inc. to Report Q1, 2024 Results on Apr 25, 2024

Now 23% undervalued

HitGen Inc.'s (SHSE:688222) 28% Jump Shows Its Popularity With Investors

Full year 2023 earnings: EPS exceeds analyst expectations

Third quarter 2023 earnings released

New minor risk - Share price stability

Consensus EPS estimates fall by 41%

Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0 in 2Q 2022)

HitGen Inc. to Report Q2, 2023 Results on Aug 23, 2023

HitGen Inc. Launches A Newly Upgraded Version of OpenDEL™, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery Research

Price target increased by 22% to CN¥23.00

First quarter 2023 earnings released: CN¥0.02 loss per share (vs CN¥0.02 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 17%

Price target increased to CN¥18.90

Third quarter 2022 earnings released: EPS: CN¥0.052 (vs CN¥0.02 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0 (vs CN¥0.06 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥28.50

Full year 2021 earnings: EPS and revenues miss analyst expectations

Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.02 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.01 (vs CN¥0.02 in 1Q 2020)

Cocrystal Pharma, Inc. Extends Drug Discovery Collaboration with HitGen and InterX, Inc

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.33 in FY 2019)

Revenue behind estimates

HitGen and UPPTHERA Entera Into Drug Discovery Research Collaboration

New 90-day high: CN¥40.13

New 90-day low: CN¥29.19

HitGen Announces License Agreement With Merck & Co., Inc., Kenilworth, NJ USA to Access Compounds for Potential Development of Novel Class of Drugs

Cedilla Therapeutics, Inc. and HitGen Inc. Announces Research Collaboration Focused on Dna-Encoded Library Based Drug Discovery

HitGen Licenses its Trk/ROS1 Inhibitor HG030 to Baiyunshan for Development and Commercialisation in China

New 90-day low: CN¥31.33

HitGen Inc. to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low: CN¥36.33

HitGen Inc. (SHSE:688222) agreed to acquire Vernalis (R&D) Limited from Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) for $25 million.

New 90-day low: CN¥37.61

New 90-day low - CN¥38.20

First half earnings released

New 90-day low - CN¥40.30

HitGen Inc. to Report First Half, 2020 Results on Aug 21, 2020

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기